Medipost, OmniaBio to enhance cooperation for CDMO business

The Canadian company OmniaBio executives visit Medipost CDMO facilities for cooperation

Canada's OmniaBio executives visiting Medipost CDMO facilities
Canada's OmniaBio executives visiting Medipost CDMO facilities
Jae-Young Han 1
2022-12-01 17:45:14 jyhan@hankyung.com
Bio & Pharma

South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on November 30 to discuss cooperation measures related to the CDMO (contract development and manufacturing organization) project.

Mitchel Sivilotti, CEO of OmniaBio, and Michael May, CEO of Commercializing Living Therapies, a parent company of OmniaBio, were in attendance at the event.

In May, Medipost announced its entry into the CDMO business and acquired a 40% stake in OmniaBio, specializing in CDMO of cell and gene therapy. In October, it launched its CDMO business for cell and gene therapy products in Korea.

Executives of OmniaBio visited the Medipost plant in Guro-gu, Seoul, and toured CDMO facilities suitable for good manufacturing practice (GMP). 

The two companies discussed ways to cooperate in strategic CDMO projects linking North America and East Asia. 

OmniaBio has decided to actively share trade secrets for process development (PD) and quality management systems.

"It was a good opportunity to directly check the excellence of MediPost's CDMO facilities and manpower," said OmniaBio CEO Sivilotti. "We will  utilize MediPost facilities and the know-how, accumulated in the process of developing Cartistem, to expand into the Asian market." 

Developed for the treatment of knee cartilage defects, Cartistem is a drug based on allogeneic umbilical cord blood-derived mesenchymal stem cells.

An official of MediPost said, "We [Medipost and OmniaBio] plan to provide a one-stop total service that embraces the entire process of developing advanced biopharmaceutical products, starting from product development to commercialization, by combining strengths of each company.


Write to Jae-Young Han at jyhan@hankyung.com
##Medipost ##OmniaBio

Medipost to expand CDMO business with 10 new clean rooms in Korea

Medipost to expand CDMO business with 10 new clean rooms in Korea

Medipost headquarters building Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO) business by building 10 clean rooms and production facilities in the country.The company said on Monday the size of

Medipost acquires Canada’s OmniaBio for CDMO business

Medipost acquires Canada’s OmniaBio for CDMO business

Medipost headquarters building Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract development and manufacturing organization (CDMO) firm, for 29.5 billion won, or C$30 million.The stake purchase is aimed

Private equity consortium buys 30% stake in biotech firm Medipost 

Private equity consortium buys 30% stake in biotech firm Medipost 

Medipost building South Korea’s first generation biotech firm Medipost Co. will sell a 30% stake to a private equity consortium, the company announced after Wednesday’s board meeting. The consortium consisting of Seoul-based Crescendo Equity Partners and SkyLake Equity Partne
(* comment hide *}